Drugs / Specificity CD38 CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03754764 | Nov 2018 → Nov 2022 | B-cell acute lymphoblastic leukemia | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Specificity CD38 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03754764 ↗ |
| Action | Deplete | “CD38 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD38.” NCT03754764 ↗ |
| Modality | Cell therapy | “CD38 CAR-T cells” NCT03754764 ↗ |
| Route | Intravenous | “The CAR-T cells will be administered by i.v. injection” NCT03754764 ↗ |
| Target | CD38 | “CD38 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD38.” NCT03754764 ↗ |